| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| A deletion in the extracellular domain of the alpha platelet derived growth factor ( PDGF ) receptor differentially impairs PDGF AA and PDGF BB binding affinities . 32D cells transfected with the human alpha platelet derived growth factor receptor ( alpha PDGFR ) bind PDGF AA , AB , and BB isoforms with high affinity , and the binding of each can be efficiently competed by all three isoforms . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| The purpose of this study was to bacterially express , purify , and refold combinations of the extracellular immunoglobulin ( Ig ) like domains ( 2 3 , 1 3 , and 1 5 ) of the human alpha platelet derived growth factor receptor ( alpha PDGFR ) to characterize molecular interactions with its ligand , platelet derived growth factor ( PDGF ) . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Northern blot analysis revealed that bFGF selectively increases the PDGF receptor alpha subtype ( PDGF R alpha ) mRNA level without a significant effect on the PDGF R beta mRNA level . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| The expression of mRNAs encoding the platelet derived growth factor ( PDGF ) subunits ( PDGF A and PDGF B ) and the PDGF receptor subunits ( PDGF R alpha and PDGF R beta ) was studied in cells of the rat testis . ^^^ Messenger RNA encoding both the PDGF R alpha and PDGF R beta subunits was observed in Leydig and Sertoli cell preparations but not in any of the germ cell samples . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| In the present study , we sought to determine the relative chemotactic potency of the three PDGF isoforms and correlate these responses to the relative abundance of the two types of PDGF cell surface receptors : PDGF alpha receptor ( PDGF R alpha ) and PDGF beta receptor ( PDGF R beta ) . ^^^ Swiss mouse 3T3 cells were assayed in parallel as a positive control cell line for PDGF R alpha and PDGF R beta expression . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Two separate PDGF receptors have been identified , PDGF R alpha and PDGF R beta . ^^^ To study the functions of PDGF R alpha and PDGF R beta in vascular SMCs , neutralizing monoclonal antibodies ( mAbs ) specific for each of the two receptors were used . ^^^ Studies with anti PDGF R alpha and anti PDGF R beta mAbs revealed that both PDGF receptors promoted the stimulatory signals for proliferation . ^^^ In addition , PDGF BB , in the presence of anti PDGF R beta , bound only to PDGF R alpha and caused suppression of SMC migration induced by fibronectin . ^^^ These results suggest that when activated by ligand binding , both PDGF R alpha and PDGF R beta stimulate proliferation . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| We have studied , at the mRNA level , the influence of various defined growth conditions on the expression of TGF alpha , PDGF BB , EGF R , PDGF R alpha , and PDGF R beta in five different glioma cell lines ( D 37MG , D 54MG , D 263MG , GaMG , and U 251MG ) . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Northern blot analysis revealed that mRNA for the PDGF receptor alpha subtype ( PDGF R alpha ) on RLF was upregulated after a 24 h exposure to asbestos in culture ( 0 . 5 15 micrograms fibers / cm2 ) . [ 125I ] PDGF BB receptor assays showed that normal RLF possess mainly PDGF R beta and a paucity of PDGF R alpha . ^^^ These data show that inorganic particulates alter the PDGF R alpha population on RLF without significant change in PDGF R beta . . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| We investigated the effect of basic fibroblast growth factor ( bFGF ) , transforming growth factor beta 1 ( TGF beta 1 ) , interleukin 1 beta ( IL 1 beta ) , and tumor necrosis factor alpha ( TNF alpha ) on the PDGF receptor system on human bronchial SMC from three different donors . bFGF induced gene expression of the PDGF alpha receptor ( PDGF R alpha ) approximately threefold without altering the PDGF beta receptor ( PDGF R beta ) . ^^^ TGF beta 1 downregulated PDGF R alpha mRNA approximately 60 % without changing PDGF R beta mRNA levels . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Proteins were examined by Western blotting and immunohistochemistry using the antibodies to PDGF AB , PDGF BB , PDGF R alpha , and PDGF R beta . ^^^ In contrast , both PDGF AB and PDGF BB immunoreactive products were present in most cell types : PDGF R alpha and PDGF R beta mainly on neurons , and PDGF R beta on some endothelial cells , with less staining of all the isoforms in the contralateral hemisphere . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| The magnitude of the fibroblast PDGF response is dependent on the number of PDGF receptor alpha ( PDGF R alpha ) relative to PDGF R beta at the cell surface . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Furthermore , linear regression analysis revealed that PDGF AA , PDGF R alpha , and PDGF R beta expression in intimal cells and PDGF BB expression in interstitial mononuclear inflammatory cells correlated with intimal thickening . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| On the mRNA level , the overall PDGF R beta expression was approximately 100 times lower than that of PDGF R alpha . ^^^ Furthermore , although PDGF R alpha mRNA levels were high irrespective of hASMC phenotype , PDGF R beta mRNA was influenced by serum stimulation with lower copy numbers in proliferating and confluent cells compared with quiescent cells . ^^^ On the protein level , quiescent hASMCs expressed 10 times more PDGF R beta than PDGF R alpha . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Reverse transcriptase polymerase chain reaction ( RT PCR ) showed that all cell lines expressed mRNA for PDGF R alpha and / or PDGF R beta ; six cell lines expressed mRNA for the PDGF A chain , with one cell line coexpressing PDGF B chain mRNA ; seven cell lines expressed mRNA for TGF alpha whereas six cell lines expressed EGF R mRNA . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Together , these data suggest that the KIT and PDGFRA genes on chromosome 4 and the FMS and PDGFRB genes on chromosome 5 arose by duplication of a common ancestral gene , followed by duplication of a chromosome . . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| It belongs to receptor tyrosine kinase subclass 3 , which also includes the colony stimulating factor 1 receptor ( c fms ) , platelet derived growth factor receptors A and B ( PDGFRA and PDGFRB ) , as well as FLT 1 and FLT3 / FLK2 . c kit and PDGFRA , c fms and PDGFRB , FLT 1 and FLT3 / FLK2 are grouped by pair in three clusters in man on chromosome 4 band q 11 q13 , chromosome 5 band q 31 q33 and chromosome 13 band q 12 respectively . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Both PDGF receptor genes ( PDGFRA and PDGFRB ) also showed no disease associations . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Accordingly , the PDGFR A and PDGFR B isoforms were shown to undergo rapid tyrosine phosphorylation on treatment with peroxynitrite . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Amplification of the EGFR , mdm 2 , CDK 4 and PDGFR A genes has been widely demonstrated in adult malignant gliomas , almost exclusively glioblastomas . ^^^ To determine the role of these mutational events in pediatric astrocytic gliomas we investigated the presence of EGFR , mdm 2 , CDK 4 and PDGFR A gene amplification in 38 childhood brain tumor biopsies , including 24 low grade astrocytomas and 14 malignant tumors . ^^^ One glioblastoma showed PDGFR A amplification , while no amplifications were observed for mdm 2 and CDK 4 genes . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Recently , a novel tyrosine kinase that is generated from fusion of the Fip 1 like 1 ( FIP1L1 ) and PDGFR alpha ( PDGFRA ) genes has been identified as a therapeutic target for imatinib mesylate in hypereosinophilic syndrome ( HES ) . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Our results confirm the high frequency of BCR ABL kinase domain mutations in patients with secondary resistance to imatinib and exclude mutations of the activation loops of KIT , PDGFRA and PDGFRB as possible causes of resistance in patients without ABL mutations . . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| However , although the incidence of MPD involving translocations of PDGFRB has been well established , to our knowledge there are only two previous reports describing a BCR PDGFRA fusion gene , in 3 patients diagnosed with atypical CML . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Complete remissions , in response to treatment with low dose imatinib mesylate ( 100 mg / day or less ) have now been documented in all cases of FIP1L1 PDGFRA ( + ) eosinophilic disorder as well as other eosinophilic disorders that carry activation mutations of the PDGFRB gene that is located on chromosome 5q33 . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| No rearrangement in PDGFRA , PDGFRB and ETV 6 genes was detected . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| In 18 patients with Costello syndrome , mutation analysis of the genes belonging to the PDGF / R family , PDGFA , PDGFB , PDGFC , PDGFD , PDGFRA , and PDGFRB , revealed no pathogenic mutations . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Imatinib mesylate is a small molecule drug that in vitro inhibits the Abelson ( Abl ) , Arg ( abl related gene ) , stem cell factor receptor ( Kit ) , and platelet derived growth factor receptor A and B ( PDGFRA and PDGFRB ) tyrosine kinases . ^^^ Similarly , the drug has now been shown to display equally impressive therapeutic activity in eosinophilia associated chronic myeloproliferative disorders that are characterized by activating mutations of either the PDGFRB or the PDGFRA gene . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| At the center of these new developments are mutations involving the platelet derived growth factor receptor genes ( PDGFRA and PDGFRB ) , which have been pathogenetically linked to clonal eosinophilia , and their presence predicts complete as well as durable treatment responses to imatinib mesylate . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| A range of cytogenetic and molecular genetic abnormalities has been recognized , including both those seen in other myeloid malignancies ( such as trisomy 8 , monosomy 7 , and 20q ) and those that are particularly linked to eosinophil differentiation ( such as rearrangements of PDGFRB , FGFR 1 , and PDGFRA , the latter with formation of a FIP1L1 PDGFRA fusion gene ) . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Imatinib ( STI 571 , Gleevec , Glivec ; Novartis Pharmaceuticals , East Hanover , NJ ) , a selective inhibitor of KIT , ABL , BCR ABL , PDGFRA , and PDGFRB , represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Clonal eosinophilia might accompany a spectrum of clinicopathological entities , the minority of whom are molecularly characterized ; Fip 1 like 1 platelet derived growth factor receptor alpha ( FIP1L1 PDGFRA ( + ) ) systemic mastocytosis , platelet derived growth factor receptor beta ( PDGFRB ) rearranged atypical myeloproliferative disorder , chronic myeloid leukemia , and the 8p11 syndrome that is associated with fibroblast growth factor receptor 1 ( FGFR 1 ) rearrangement . ^^^ For example , the presence of either PDGFRA or PDGFRB mutations warrants the use of imatinib in clonal eosinophilia . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Rearrangements involving the platelet derived growth factor receptor genes ( PDGFRA and PDGFRB ) , both tyrosine kinase receptors , have been demonstrated to be pathogenetically linked to the dysregulated clonal overproduction of eosinophils . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Some of the Ph negative myeloproliferative diseases are characterized by other chromosomal translocations involving a variety of tyrosine kinase genes , including ABL 1 , ABL 2 , PDGFRA , PDGFRB , FGFR 1 , and JAK 2 . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Nevertheless , the presence of a PDGFR a / PDGFA and c Kit / SCF autocrine / paracrine stimulation loop in a proportion of cases , supports the potential role of specific tyrosine kinase inhibitors in the treatment of gliosarcomas . . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| The current review focuses on the diagnosis and treatment of both molecularly defined and clinicopathologically assigned categories of atypical MPD : chronic myelomonocytic leukemia , juvenile myelomonocytic leukemia , chronic neutrophilic leukemia , chronic basophilic leukemia , chronic eosinophilic leukemia , idiopathic eosinophilia including hypereosinophilic syndrome , systemic mastocytosis , unclassified MPD , and eosinophilic / mast cell disorders associated with mutations of platelet derived growth factor receptors alpha ( PDGFRA ) and beta ( PDGFRB ) , FGFR 1 , and KIT . . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Rearrangements involving PDGFRA and PDGFRB in eosinophilic chronic myeloproliferative disorders , and of fibroblast growth factor receptor 1 ( FGFR 1 ) in the 8p11 stem cell myeloproliferative syndrome constitute additional examples of specific genetic alterations linked to clonal eosinophilia . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| Tumor specimens were analyzed for mutations of KIT , PDGFRA , PDGFRB , and CTNNB 1 ( beta catenin ) . ^^^ Tumor expression of total and activated KIT , PDGFRA , and PDGFRB were assessed using immunohistochemistry and immunoblotting techniques . ^^^ No mutations of KIT , PDGFRA , or PDGFRB were found . ^^^ AF tumors expressed minimal to null levels of KIT and PDGFRA but expressed levels of PDGFRB that are comparable with normal fibroblasts . ^^^ |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P16234 and P09619 |
Pubmed |
SVM Score :0.0 |
| NA |
|